Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.

Drug Discovery Services Market Revenue Outlook: What CAGR Is Expected Through 2030?

The domain of drug discovery services is witnessing substantial expansion, projected to ascend from $20.52 billion in 2025 to $23.21 billion in 2026, reflecting a compounded annual growth rate (CAGR) of 13.1%. This upward trajectory, observed over the preceding years, is underpinned by escalating pharmaceutical research and development investments, increasing cost constraints faced by pharmaceutical entities, the burgeoning CRO sector, advancements in target-centric drug discovery methodologies, and the fostering of cooperative ventures between academic institutions and industry players.

The drug discovery services sector is poised for substantial expansion, projecting a market value of $39.79 billion by 2030, driven by a robust 14.4% compound annual growth rate. This upward trajectory is fueled by advancements in precision medicine, the increasing adoption of AI-powered discovery tools, a surge in funding for biotech startups, intensified research into intricate diseases, and a growing imperative for accelerated lead optimization. Key developments shaping this landscape include a noticeable shift towards outsourcing drug discovery functions, heightened utilization of artificial intelligence in pinpointing therapeutic targets, the broadening scope of early-stage discovery services, a heightened demand for biologic drug development, and the synergistic integration of both in vitro and in vivo research methodologies.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=8324&type=smp

Drug Discovery Services Market Opportunity Drivers: What Is Creating New Revenue Potential?

The increasing incidence of long-term health conditions is anticipated to be a significant driver for the expansion of the drug discovery services sector. These chronic ailments, characterized by their enduring nature and often uncurable yet manageable status, necessitate continuous innovation in pharmaceutical solutions. Drug discovery services are instrumental in pinpointing and formulating novel therapeutic agents for managing such persistent illnesses. Illustratively, data from the World Health Organization, a global intergovernmental health body headquartered in Switzerland, indicated in September 2023 that chronic noncommunicable diseases accounted for 41 million fatalities each year, a figure representing three-quarters of all worldwide deaths. Consequently, the escalating prevalence of these chronic conditions is poised to foster growth within the drug discovery services market.

Drug Discovery Services Market Segment Performance And Strategic Opportunities

The drug discovery services market covered in this report is segmented –

1) By Type: Chemistry Services, Biology Services

2) By Process: Target Selection, Target Validation, Hit-To-Lead identification, Lead Optimization, Candidate Validation

3) By Drug Type: Biologics Drug , Small Molecule Drug

4) By End user: Pharmaceutical And Biotechnology Companies, Academic Institutes, Other End Users

Subsegments:

1) By Chemistry Services: Medicinal Chemistry, Compound Management, High-Throughput Screening, Lead Optimization

2) By Biology Services: In Vitro Studies, In Vivo Studies, Pharmacokinetics And Pharmacodynamics (PK Or PD), Biomarker Discovery

Drug Discovery Services Market Innovation Trends Driving Future Development

Leading players in the drug discovery services sector are actively integrating cutting-edge technologies like artificial intelligence and machine learning to boost both the speed and precision of developing new medications. Artificial intelligence, in essence, involves creating computational systems capable of tasks demanding human-like intellect, while machine learning, a branch of AI, concentrates on algorithms and statistical approaches allowing computers to acquire knowledge from data and subsequently forecast or decide based on that information. As an illustration, in February of 2024, Eurofins Discovery, a prominent French firm offering support services to industries including pharmaceuticals, unveiled a novel system named DiscoveryAI SAFIRE, which stands for Suite of ADMET Predictions for In Silico Refinement and Evaluation. This sophisticated system employs exclusive datasets, alongside artificial intelligence and machine learning, to improve drug discovery workflows. The SAFIRE platform aims to accelerate the identification of novel drug candidates by forecasting the ADMET characteristics of various compounds. It draws upon information contained within Eurofins Discovery’s substantial BioPrint database, a repository diligently assembled through years of dedicated research.

Drug Discovery Services Market Key Players: Which Companies Shape Industry Competition?

Major companies operating in the drug discovery services market are Thermo Fisher Scientific Inc., Albany Molecular Research Inc., Charles River Laboratories International Inc., Laboratory Corporation of America Holdings, Domainex Ltd., GenScript Biotech Corporation, Pharmaceutical Product Development LLC, Advinus Therapeutics Pvt. Ltd., Jubilant Biosys Ltd., Evotec AG, Syngene International Ltd., Bayer AG, Merck KGaA, Ubiquigent Ltd., Eurofins Scientific SE, AppTec Laboratory Services Inc., GVK Biosciences Private Limited, Aurigene Discovery Technologies Limited, Viva Biotech Holdings, Pharmaron Beijing Co. Ltd., Selcia Limited, Concept Life Sciences Group Limited, BioDuro LLC, ChemPartner Corporation, Aptuit LLC, Sygnature Discovery Limited, Peak Proteins Ltd., SRI International, BioAscent Discovery Limited, Sai Life Sciences Limited, Promega Corporation, MedChemExpress LLC, Aragen Bioscience Inc., WuXi STA, BioNTech SE, Moderna Inc., Gilead Sciences Inc., Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals Inc., Amgen Inc., Bristol-Myers Squibb Company

Access The Complete Drug Discovery Services Market Report:

https://www.thebusinessresearchcompany.com/report/drug-discovery-services-global-market-report

Drug Discovery Services Market Regional Outlook: Where Are The Largest Opportunities Located?

North Americawas the largest region in the drug discovery services market in 2025. The regions covered in the drug discovery services market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model